Published On: November 13th, 2024Categories: Trade Ideas
In this investment case, we highlight Teva Pharmaceutical Industries, one of the world’s largest generic drug manufacturers, showing momentum in both branded and generic medicines. Teva’s stabilization in generics, progress with complex generics and biosimilar approvals, and key branded products like Austedo and Ajovy support its growth trajectory. With major legal issues resolved, significant leverage reduction, and rating upgrades with a positive outlook, Teva is well-positioned as a “rising star” with potential for an investment-grade rating in the medium term.
Don’t miss our latest publication! Discover us on www.bridport.ch
